Kazumi T, Yoshino G, Ohki A, Matsuba K, Ino T, Amano M, Kasuga M
Department of Medicine, Hyogo Medical Center for Adults, Akashi, Japan.
Horm Metab Res. 1995 May;27(5):239-43. doi: 10.1055/s-2007-979948.
Effects of 12 months of simvastatin treatment were examined in 48 NIDDM patients with total serum cholesterol levels exceeding 220 mg/dl and were compared with those in 35 nondiabetic patients with hypercholesterolemia. In the diabetic group, 5-10 mg of simvastatin given once daily at bedtime significantly lowered total cholesterol (21%). LDL cholesterol (28%), apoB (15%) and triglycerides (8%) levels. These changes were identical to those in the nondiabetic group, except for triglycerides which did not change significantly. HDL cholesterol increased significantly in the nondiabetic group but not in the diabetic group. The reductions in LDL cholesterol and apoB in hypercholesterolemic patients with NIDDM were not influenced by gender, age, glycemic control, the presence or absence of systemic hypertension, obesity and overt proteinuria. In addition, the decrease in LDL cholesterol was not affected by the number of risk factors per patient. Simvastatin did not significantly alter hemoglobin A1c or fasting plasma glucose and was well tolerated in both groups. Simvastatin produced beneficial effects on serum lipids and apolipoproteins and neutral effects on glycemic control in hypercholesterolemic patients with NIDDM, whether or not they had an additional atherosclerotic risk factor.
对48名总血清胆固醇水平超过220mg/dl的非胰岛素依赖型糖尿病（NIDDM）患者进行了为期12个月的辛伐他汀治疗效果研究，并与35名非糖尿病高胆固醇血症患者进行了比较。在糖尿病组中，每晚睡前服用5 - 10mg辛伐他汀可显著降低总胆固醇（21%）、低密度脂蛋白胆固醇（28%）、载脂蛋白B（15%）和甘油三酯（8%）水平。这些变化与非糖尿病组相同，但甘油三酯变化不显著。高密度脂蛋白胆固醇在非糖尿病组显著升高，而在糖尿病组未升高。NIDDM高胆固醇血症患者的低密度脂蛋白胆固醇和载脂蛋白B降低不受性别、年龄、血糖控制、是否存在系统性高血压、肥胖和显性蛋白尿的影响。此外，每位患者的危险因素数量对低密度脂蛋白胆固醇的降低没有影响。辛伐他汀对糖化血红蛋白或空腹血糖没有显著影响，两组患者耐受性良好。辛伐他汀对NIDDM高胆固醇血症患者的血脂和载脂蛋白产生有益作用，对血糖控制产生中性作用，无论他们是否有其他动脉粥样硬化危险因素。
